Arrowhead Pharmaceuticals (ARWR) Current Assets (2010 - 2026)

Arrowhead Pharmaceuticals' Current Assets history runs 17 years deep, the most recent figure standing at $1.8 billion for Q1 2026.

• Quarterly Current Assets rose 62.06% year-over-year to $1.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 billion (up 62.06% YoY) and the FY2025 annual result came in at $950.6 million, up 36.69% from the prior year.
• Current Assets was $1.8 billion for Q1 2026 at Arrowhead Pharmaceuticals, up from $1.2 billion in the prior quarter.
• Across five years, Current Assets topped out at $1.8 billion in Q1 2026 and bottomed at $237.9 million in Q4 2023.
• A 5-year average of $696.1 million and a median of $570.5 million in 2024 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2023 — Current Assets sank 58.63% — and 2024, when it jumped 139.82%.
• Arrowhead Pharmaceuticals' Current Assets stood at $575.0 million in 2022, then sank by 58.63% to $237.9 million in 2023, then surged by 139.82% to $570.5 million in 2024, then surged by 105.84% to $1.2 billion in 2025, then soared by 56.66% to $1.8 billion in 2026.
• Business Quant data shows ARWR's Current Assets at $1.8 billion in Q1 2026, $1.2 billion in Q4 2025, and $950.6 million in Q3 2025.